ModifiedUnitedHealthcarePolicy CS082KY.12

Neurophysiologic Testing and Monitoring (for Kentucky Only)

Medical policy governing neurophysiologic testing and monitoring services for members in Kentucky, including coverage stance for EMG, NCS, and other neurophysiologic tests and technologies.

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring (for Kentucky Only)

Policy CodePolicy CS082KY.12

Change TypeCoverage clarifications and pediatric additions

Effective DateMay 1, 2026

Next Review Date

Key ActionWhen requesting coverage, document the diagnosis, testing performed, and for pediatric claims show that needle EMG was performed with nerve conduction studies where required.

SourceLink

POLICY UPDATE CHANGES

Added language specifying that nerve conduction studies (with or without standard late responses) and neuromuscular junction testing when performed with needle EMG are proven and medically necessary for peripheral neuropathy/polyneuropathy, plexopathy, neuromuscular junction disorders, and myopathy in members under 18 years of age.

Clarified that nerve conduction studies performed without needle EMG are medically necessary for certain disorders (radiculopathy; guidance for injections; evaluation for carpal tunnel; individuals on anticoagulants or with lymphedema) when specific clinical indications exist.

Declared nerve conduction studies for all other conditions and non-invasive/automated point-of-care devices that only test distal motor latencies and conduction velocities as unproven and not medically necessary.

Added language indicating nerve conduction studies with or without standard late responses and for neuromuscular junction testing when performed with needle EMG are proven and medically necessary for several pediatric indications including peripheral neuropathy, plexopathy, neuromuscular junction disorders, and myopathy.

Clarified that nerve conduction studies without needle EMG are unproven and not medically necessary for conditions other than a limited set (e.g., radiculopathy, certain treatment guidance, anticoagulated patients, lymphedema, and carpal tunnel evaluation).

Removed CPT/HCPCS codes 95999 and A9279 from the Applicable Codes list.

Updated supporting sections (Description of Services, Clinical Evidence, FDA, References) and archived previous policy version CS082KY.11.

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

KentuckyApplies only to

Members <18Pediatric coverage added

listedUnproven / NMN modalities

multipleCodes listed

POC NCS & macro-EMGEvidence weak for

0.91Wearable GTCS sensitivity

Coverage Criteria and Clinical Policy

inv-01: Proven and medically necessary indications

Covered when meeting indications

Primary covered indications for NCS/EMG: Nerve conduction studies with or without standard late responses and needle electromyography are proven and medically necessary for known or suspected: peripheral neuropathy/polyneuropathy (e.g., inherited, metabolic, traumatic, entrapment syndromes); plexopathy; neuromuscular junction disorders (e.g., myasthenia gravis); myopathy; motor neuron disease; radiculopathy (cervical, thoracic, lumbosacral); and for treatment guidance such as precise muscle localization for botulinum toxin injections when required to identify affected muscles.

Includes NCS with or without late responses and NCS without EMG in specified clinical situations.

inv-02: NCS without EMG — permitted circumstances

Covered without needle EMG when specific conditions are present

NCS without needle EMG allowed: Nerve conduction studies with or without standard late responses when performed without needle electromyography are medically necessary for individuals with one of the covered disorders who have any of the following clinical indications: are treated with anticoagulants; have lymphedema; or are being evaluated for carpal tunnel syndrome.

Explicitly allows NCS alone for these scenarios.

inv-03: Medical necessity criteria (AANEM-based)

Covered when clinical indication aligns with AANEM-recommended uses and minimum standards are met:

AANEM minimum standards: Testing is medically indicated AND performed using equipment that assesses all parameters (not screening-only equipment) AND performed by a physician or by a trained technician under the direct supervision of a physician; the EMG must be performed by a trained physician and one physician should supervise and perform components of the exam.

AANEM recommended policy; see referenced guidance.

Indications for electrodiagnostic testing: Focal neuropathies or entrapment syndromes for localization OR traumatic nerve lesions for diagnosis/prognosis OR generalized neuropathies (diabetic, uremic, metabolic, toxic, hereditary, immune-mediated) OR neuromuscular junction disorders OR radiculopathy, plexopathy, myopathy, or when precise muscle localization for injections is required OR symptom-based presentations (pain, weakness, sensory disturbance) when pre-test evaluation is inconclusive.

Summarizes AANEM model policy indications.

When EDX testing is low yield (generally not indicated): Mild, symmetric, distal, predominantly sensory neuropathy with a known cause (e.g., diabetes) and little suspicion of a coexisting nerve disorder — electrodiagnostic testing is likely low yield and generally not indicated.

inv-04: Investigational or limited evidence technologies

Not covered/considered investigational or used with caution when evidence is weak:

Macro-EMG: Macro-electromyography (Macro-EMG) testing has weak evidence in the peer-reviewed literature; further robust studies are needed and its effect on patient management is unclear.

Evidence limitations noted; see Macro-EMG review.

Point-of-care/portable NCS devices: Automatic, portable, or point-of-care nerve conduction monitoring systems have limited evidence from small series and preliminary studies; patient-relevant outcomes and clinical utility are not well established.

Evidence limited to small studies; validation needed.

Wearable physiologic seizure/movement recording: Physiologic recording using wearable accelerometers, EMG, electrodermal sensors or gyroscopes shows promising technical performance for some applications but overall evidence is weak and heterogeneous for routine clinical decision-making beyond specific seizure types.

Further robust validation required.

inv-05: Wearable seizure-detection — recommended use

Professional guidance and evidence summary regarding wearable seizure detection

Wearable detection for GTCS/FBTCS: Use clinically validated wearable devices for automated detection of generalized tonic-clonic seizures (GTCS) and focal to bilateral tonic-clonic seizures (FBTCS) when significant safety concerns exist (for example, unsupervised individuals who do not share a bedroom) and when alarms can enable rapid intervention (within approximately 5 minutes).ILAE-IFCN conditional recommendation

Recommendation is weak/conditional; devices currently supported primarily for GTCS/FBTCS detection.

inv-06: Wearable devices — performance evidence

Evidence findings that inform coverage decisions

Performance characteristics: Meta-analysis of noninvasive wearables for tonic-clonic seizures reports mean sensitivity approximately 0.91 and overall false alarm rate (FAR) about 2.1 per 24 hours; sensitivity was similar between wrist-worn and surface devices but FAR was higher for wrist-worn devices; performance for focal seizures and PNES is variable and generally lower.sensitivity=0.91; FAR=2.1/24 h

High heterogeneity and limited recording durations in studies.

inv-07: Quantitative Sensory Testing — coverage stance

Position on QST utility and limitations

QST is investigational or limited utility: Quantitative Sensory Testing (QST) has weak to mixed evidence for predicting clinical outcomes; results are methodology-dependent, require full subject cooperation, do not localize lesion, and should not be used as the sole diagnostic method. Specific QST measures (e.g., vibration and thermal thresholds) may be probably effective for documenting diabetic neuropathy, but overall predictive and prognostic utility is inconsistent and additional high-quality studies are needed.Level B for some diabetic neuropathy uses; otherwise insufficient (Level U)

Society guidance emphasizes reproducible instruments, strict protocols, and calibration.

inv-08: Evidence-derived coverage considerations

Summarized evidence and professional society guidance relevant to coverage:

QST use conditions: QST may be considered only when using instruments and methodologies demonstrated to be reproducible, with strict machine calibration and testing protocols followed; results cannot localize lesions and depend on full cooperation of the subject.

Reproducibility and methodology emphasized by AAN and AANEM.

sNCT status: Current perception threshold/sensory nerve conduction threshold test (sNCT) is identified as investigational by the AANEM model policy and is considered unsupported for coverage decisions.

AANEM model policy identifies sNCT as investigational.

sEMG clinical utility: Surface EMG (sEMG) applications, including sEMG-based seizure monitoring and other proposed uses, show mixed and often low-quality evidence; diagnostic accuracy varies by placement and indication, and additional well-designed studies are needed before broad coverage absent demonstrated patient-relevant outcomes.

AANEM practice topic notes insufficient data for many sEMG uses.

inv-09: NCS + needle EMG — Proven / Medically Necessary (pediatrics)

Covered when ALL of the following are met for Members Under 18:

Pediatric NCS with needle EMG: Nerve conduction studies with or without standard late responses and neuromuscular junction testing when performed in conjunction with needle electromyography are proven and medically necessary for known or suspected: peripheral neuropathy/polyneuropathy (including inherited, metabolic, traumatic, entrapment syndromes); plexopathy; neuromuscular junction disorders (e.g., myasthenia gravis); and myopathy in members under 18 years of age.

Applies to members under 18 per policy revision effective 05/01/2026.

inv-10: NCS without needle EMG — Covered with indication

Covered when ALL of the following clinical indications exist (NCS without needle EMG):

Allowed indications for NCS without needle EMG: Radiculopathy (cervical, thoracic, or lumbosacral); treatment guidance such as muscle localization for botulinum toxin injections when required to identify affected muscles; individuals treated with anticoagulants; individuals with lymphedema; and individuals being evaluated for carpal tunnel syndrome.

These are the specific scenarios where NCS without needle EMG is considered medically necessary.

inv-11: Unproven / Not Medically Necessary

Not medically necessary when ANY of the following apply:

Unproven uses: Nerve conduction studies for all other conditions not listed as covered; and non-invasive automatic, portable, or automated point-of-care nerve conduction monitoring systems that test only distal motor latencies and conduction velocities for electrodiagnostic testing.

Declared unproven due to insufficient evidence of efficacy.

inv-12: Coverage, Permitted Uses, and Not Medically Necessary Items

Coverage statements from this document include:

Proven and medically necessary for pediatric patients when performed with needle EMG: Nerve conduction studies with or without standard late responses and neuromuscular junction testing when performed in conjunction with needle electromyography are proven and medically necessary for known or suspected peripheral neuropathy/polyneuropathy, plexopathy, neuromuscular junction disorders (e.g., myasthenia gravis), and myopathy in members under 18.

Policy addition effective 05/01/2026.

Permitted without EMG for specific indications: Nerve conduction studies without needle EMG may be considered for radiculopathy (cervical, thoracic, lumbosacral), for treatment guidance such as muscle localization for botulinum toxin injections when required, for individuals on anticoagulants, individuals with lymphedema, and individuals being evaluated for carpal tunnel syndrome.

Specific scenarios where NCS alone is allowed.

Unproven and not medically necessary: Nerve conduction studies for all other conditions and non-invasive automatic, portable, or automated point-of-care nerve conduction monitoring systems that test only distal motor latencies and conduction velocities are unproven and not medically necessary. Additionally, macro-EMG, SEMG, sMMG, wearable physiologic seizure/movement monitoring, SEMG-based seizure monitoring systems, quantitative sensory testing (QST), and visual evoked potential testing for glaucoma are listed as unproven/not medically necessary.

This policy identifies a set of neurophysiologic modalities that are considered unproven and not medically necessary because peer-reviewed evidence does not demonstrate consistent, patient‑relevant benefit. Listed modalities include macro‑EMG (macroelectromyography), non‑invasive automatic/portable/point‑of‑care nerve conduction systems that test only distal motor latencies and conduction velocities, physiologic wearable monitoring for seizure or movement disorders (accelerometers, electrodermal sensors, gyroscopes, wrist devices, smartwatches), SEMG‑based seizure monitoring systems, surface electromyography (SEMG), surface mechanomyography (sMMG), quantitative sensory testing (QST) methods (including monofilament, pressure‑specified, computer‑assisted exams, and current perception threshold testing), and visual evoked potential testing for glaucoma. These modalities are explicitly listed in the policy as not covered due to insufficient evidence of efficacy.

The policy recognizes limited circumstances in which nerve conduction studies (NCS) may be performed without concomitant needle EMG. Per AANEM guidance and the policy summary, reporting NCS and needle EMG as separate, non‑integrated reports is generally inappropriate; exceptions exist when clinical indications or patient factors justify NCS alone. The policy explicitly permits NCS without needle EMG for specified scenarios (for example, evaluation of carpal tunnel syndrome, individuals on anticoagulants, or persons with lymphedema) when those clinical indications are documented.

Quantitative Sensory Testing (QST) is methodology‑ and cooperation‑dependent and therefore has important limitations. Professional guidance states QST should not be used as the sole diagnostic method, requires strict machine calibration and reproducible protocols, and different instruments/protocols produce non‑equivalent results. Although some QST measures (eg, vibration and thermal thresholds) have evidence supporting documentation of diabetic neuropathy (Level B), overall predictive and prognostic utility is inconsistent; consequently QST performed without validated, reproducible methods is considered investigational or not medically necessary.

Several tests and technologies are identified as investigational or supported by only limited evidence and therefore are treated as unproven for routine coverage. These include macro‑EMG (evidence weak and unclear effect on management), point‑of‑care or portable automated NCS devices (small case series and limited comparative data), SEMG and SEMG‑based seizure monitoring systems (heterogeneous evidence and variable diagnostic accuracy), and sMMG with IMU systems (few published studies and insufficient evidence of improved health outcomes). The policy advises these technologies require more robust, patient‑centered outcome data before being considered medically necessary.

Non‑invasive automatic, portable, or automated point‑of‑care nerve conduction monitoring systems that assess only distal motor latencies and conduction velocities are specifically singled out as not medically necessary. Preliminary studies are promising but primarily small and methodologically limited; the policy therefore classifies these single‑metric, screening‑oriented devices as investigational pending robust evidence demonstrating meaningful patient outcomes.

This policy does not address intraoperative neurophysiologic testing. Intraoperative monitoring and its indications, methods, and coverage are outside the scope of this document and should be evaluated under separate intraoperative monitoring policies or benefit provisions.

Beyond the specified covered indications, the policy declares NCS performed for other conditions to be unproven and not medically necessary. NCS alone (or NCS reported separately from EMG) for indications not listed among the policy's supported diagnoses lacks sufficient evidence and may be denied. The policy emphasizes that proper electrodiagnostic evaluation generally integrates both NCS and needle EMG per professional standards.

The evidence supporting several emerging neurophysiologic technologies is limited by small studies, heterogeneous methods, and uncertain impact on clinical management. For wearable seizure‑detection and movement monitoring, meta‑analyses report promising sensitivity for tonic‑clonic seizures but high heterogeneity, short recording durations, and elevated false alarm rates; for point‑of‑care NCS and macro‑EMG the literature consists largely of small case series. Collectively, these limitations justify declaring many of these modalities investigational until larger, well‑designed studies demonstrate reproducible results and patient‑relevant benefits.

Wearable seizure‑detection devices show the most consistent performance for generalized tonic‑clonic seizures (GTCS/FBTCS) and are not supported for reliable detection of many focal seizures or psychogenic nonepileptic seizures. The policy therefore limits routine coverage for wearable devices to scenarios aligned with guideline recommendations (eg, GTCS/FBTCS detection when safety concerns exist) and does not support use of wearables for broad detection of other seizure types because available studies show variable sensitivity and limited real‑world validation.

Surface EMG (sEMG) and surface mechanomyography (sMMG) applications are affected by heterogeneous study designs and inconsistent diagnostic accuracy across conditions. AANEM practice guidance notes insufficient data to support sEMG for distinguishing neuropathic versus myopathic disorders and highlights level‑U evidence for many proposed uses. As a result, sEMG/sMMG are considered investigational or not medically necessary for indications lacking high‑quality outcome evidence or reproducible methodologies.

The policy reiterates that nerve conduction studies performed for indications other than those specifically listed as covered are considered unproven and not medically necessary. Additionally, single‑metric automated point‑of‑care NCS systems, macro‑EMG, SEMG, sMMG, wearable physiologic monitoring for seizures or movement disorders, SEMG‑based seizure systems, QST, and VEP for glaucoma are explicitly named among non‑covered modalities.

Summary list of modalities considered not medically necessary or investigational: macro‑EMG; non‑invasive automatic/portable/point‑of‑care NCS devices that test only distal motor latencies and conduction velocities; physiologic wearable seizure/movement monitoring devices (including wrist‑worn accelerometer/gyroscope systems and SEMG‑based seizure monitors); surface electromyography (SEMG); surface mechanomyography (sMMG); quantitative sensory testing (QST) and current perception threshold testing; and visual evoked potential (VEP) testing for glaucoma. These are listed in the policy as unproven and not medically necessary pending stronger supporting evidence.

Coding: CPT, HCPCS, and Device Codes

Applicable CPT codesCPT

0106T	Quantitative sensory testing (QST), testing and interpretation per extremity; using touch pressure stimuli to assess large diameter sensation.
0107T	Quantitative sensory testing (QST), testing and interpretation per extremity; using vibration stimuli to assess large diameter fiber sensation.
0108T	Quantitative sensory testing (QST), testing and interpretation per extremity; using cooling stimuli to assess small nerve fiber sensation and hyperalgesia.
0109T	Quantitative sensory testing (QST), testing and interpretation per extremity; using heat-pain stimuli to assess small nerve fiber sensation and hyperalgesia.
0110T	Quantitative sensory testing (QST), testing and interpretation per extremity; using other stimuli to assess sensation.
0464T	Visual evoked potential, testing for glaucoma, with interpretation and report.
0778T	Surface mechanomyography (sMMG) with concurrent application of inertial measurement unit (IMU) sensors for measurement of multi-joint range of motion, posture, gait, and muscle function.
95860	Needle electromyography; 1 extremity with or without related paraspinal areas.
95861	Needle electromyography; 2 extremities with or without related paraspinal areas.
95863	Needle electromyography; 3 extremities with or without related paraspinal areas.

1–10 of 34

1/4

Applicable HCPCS/Supply codesHCPCS

A9280	Alert or alarm device, not otherwise classified.
G0255	Current perception threshold/sensory nerve conduction test, (SNCT) per limb, any nerve.
S3900	Surface electromyography (EMG).

Codes referenced (none listed)mixed

CPT/HCPCS not listed in this excerpt

No explicit procedure or diagnosis codes are provided in these chunks.

Regulatory / Device codesmixed

IKN	FDA product code for EMG devices (informational)

FDA product codes (EMG)mixed

IKN	FDA product code referenced for EMG devices

FDA product codes (QST / sensory)mixed

LLN	Product code for vibration threshold measurement device / QST
GXB	Product code for esthesiometer / QST / temperature discrimination
LQW	Product code referenced for sensory threshold testing
GWI	Product code for 2-point discriminator / QST

FDA product codes (point-of-care NCS)mixed

JXE	Product code for point-of-care nerve conduction devices

FDA product codes (physiologic recording / VEP)mixed

POS	Product code for physiologic recording of movement/seizure monitoring
GYD	Alternate product code for physiologic recording
GWE	Product code for evoked response photic stimulators
HLX	Product code for evoked response photic stimulators
GWQ	Product code for EEG recording devices capturing visual signals

Removed CPT/HCPCS CodesCPT | HCPCS

95999	Removed
A9279	Removed

Electrodiagnostic evaluation components

Core componentsProper electrodiagnostic (EDX) evaluation generally includes both nerve conduction studies (NCS) and needle electromyography (EMG)

Late response testingLate response tests (F‑wave, H‑reflex) are complementary to NCV and may be necessary; in some cases a late response may be the only abnormality

Integrated reportingNCS and needle EMG are typically performed and interpreted together during the same evaluation per AANEM guidance

Wearable recording median recording time

Provider Guidance, Prior Authorization, and Documentation

Prior Authorization

Prior authorization expectation

Prior authorization expectations vary by contract. Prior authorization may be required for advanced electrodiagnostic procedures or investigational devices. When prior authorization is required, submit documentation that justifies medical necessity and shows how the requested testing will affect clinical management.

Check member-specific plan and state/federal contract rules before ordering testing.
When requesting prior authorization, include the clinical question to be answered and how results will change management.

Note

Prior authorization — informational

Prior authorization — informational: FDA clearance or approval does not by itself establish medical necessity or coverage. Use of devices or tests described as investigational, not reproducible, or lacking validated protocols may be denied even if FDA-cleared.

Codes listed in the Applicable Codes section are for reference only and do not guarantee coverage.
Removed codes (e.g., 95999, A9279) should not be used for prior authorization requests.

Background and Scope

Neurophysiologic testing (electrodiagnostic studies) evaluates peripheral nerve and muscle function and complements history and physical examination. Proper electrodiagnostic evaluation typically integrates nerve conduction studies (NCS) and needle electromyography (EMG), and may include late response testing (eg, F‑wave, H‑reflex) when clinically indicated. Professional society guidance emphasizes that testing be medically indicated, performed with equipment that measures full signal parameters (not screening‑only devices), and conducted by appropriately qualified personnel under physician supervision, with integrated real‑time interpretation.

Definitions and Test Descriptions

Needle EMG definition

DefinitionNeedle electromyography requires insertion of needles through the skin into muscle to evaluate whether weakness is due to nerve, neuromuscular junction, or muscle pathology

Clinical roleUsed to evaluate individual nerves and muscles and to help distinguish neuropathic, neuromuscular junction, or myopathic causes of weakness

Relation to SEMGDistinct from surface EMG; needle EMG is invasive and generally performed by a trained physician

Surface EMG (SEMG) definition

DefinitionSurface EMG (SEMG) is a noninvasive technique with electrodes placed on the skin to measure underlying muscle electrical activity

ApplicationsIncludes paraspinal EMG and has been used in seizure-monitoring systems (e.g., arm/biceps placement for GTCS detection)

Policy Summary

PayerUnitedHealthcare

PolicyNeurophysiologic Testing and Monitoring (for Kentucky Only)

Policy CodePolicy CS082KY.12

Change TypeCoverage clarifications and pediatric additions

Effective DateMay 1, 2026

Next Review Date

Key ActionWhen requesting coverage, document the diagnosis, testing performed, and for pediatric claims show that needle EMG was performed with nerve conduction studies where required.

SourceLink

On This Page

AANEM guidance identifying low-yield scenarios.

sMMG and IMU systems: Surface mechanomyography (sMMG) often combined with inertial measurement units lacks sufficient published evidence to conclude benefit on health outcomes.

Insufficient evidence for coverage expansion.

icVEP for glaucoma: Isolated-check visual evoked potential (icVEP) demonstrates promising diagnostic metrics in pooled analyses (example pooled sensitivity ~77% and specificity ~93%) but heterogeneity and limited high-quality trials limit definitive conclusions; icVEP may be considered adjunctive to structural and functional testing.

Further research required before definitive coverage.

These items are declared unproven or not medically necessary due to insufficient evidence.

Median recording time

Median recording time per patient in wearable seizure-detection studies was 52.9 hours

Study scopeMeta-analysis included 23 studies eligible for pooled analysis (28 identified overall) and 1,269 individuals

Device types assessedStudies investigated wrist/ankle accelerometry devices and wearable surface EMG devices

icVEP Signal-to-Noise Ratio (SNR) examples

Reported SNR cutoffsStudies report various icVEP signal‑to‑noise ratio (SNR) cutoffs (examples: cutoff SNR = 1; cutoff SNR = 0.85; cutoff SNR = 0.93)

Cutoff dependenceDiagnostic sensitivity and specificity depend on chosen SNR cutoff (e.g., Xu et al: cutoff 0.85 vs 1 produced different sensitivity/specificity)

Meta-analysis performance2025 meta-analysis pooled icVEP sensitivity ~77% and specificity ~93%, with study heterogeneity noted

Documentation Required

Clinical impact documentation

Document the clinical impact of testing. Prior authorization and claim review require clear evidence that test results were used to guide diagnosis or change management (treatment decisions, procedures, referrals, or medication changes).

Report specific management changes that occurred because of the test (for example: targeted muscle localization for botulinum toxin injection, initiation or change of therapy, referral for surgery or device-assisted therapy).
If objective device or wearable-derived measurements prompted the referral or treatment change, include comparative values or summary interpretation in the record.

Documentation Required

Instrument and protocol documentation

Instrument and protocol documentation: Use only validated, reproducible instruments and calibrated protocols. Provide device model, manufacturer, testing protocol, calibration/maintenance records, and evidence of validation when requesting coverage for QST, wearable devices, or other nonstandard modalities.

For QST: specify the instrument, stimulus modality (vibration, cooling, heat, touch/pressure), test environment, normative values used, and calibration status.
For wearable or sensor-based devices: provide device name, hardware/software version, algorithm description, duration of monitoring, and peer-reviewed evidence of validity if available.

Documentation Required

Objective measurement to support referral (wearable-derived measures)

Objective measurement to support referral: When referring based on wearable-derived or device-generated metrics, include the objective summary measures, thresholds or classifier scores used, duration of monitoring, and how those measures align with published validation or clinical utility evidence.

Examples: PKG or KinetiGraph summary scores and monitoring duration; classifier probabilities or thresholds used to trigger referral for device-assisted therapy.
Include the clinical context (symptom history, exam findings) that prompted use of the device and how objective data complemented the evaluation.

Note

Plan term check — apply policy in context of federal/state/contractual requirements

Plan term check: Apply this policy in the context of federal, state, and contractual requirements. In the event of conflict between this policy and a member's plan or legal requirement, the federal/state/contractual terms govern.

Verify member-specific coverage rules before submitting prior authorization or claims.
UnitedHealthcare reserves the right to modify policies; always confirm the effective date (Policy CS082KY.12 effective 2026-05-01) and any plan-specific rules.

Evidence statusOverall evidence for SEMG and SEMG‑based seizure monitoring is weak; further robust studies are needed

Nerve Conduction Studies (NCS) definition

DefinitionNerve conduction studies (NCS) assess peripheral nerve function by measuring conduction velocity, latency, amplitude, and response shape

Complementary testingNCS are generally performed with needle EMG to form a complete electrodiagnostic evaluation per AANEM standards

Late responsesIncludes late response testing (F‑wave, H‑reflex) which may be performed during the same evaluation

Neuromuscular junction testing definition

DefinitionNeuromuscular junction testing (repetitive nerve stimulation or single‑fiber EMG) records muscle responses to series of nerve stimuli to diagnose disorders like myasthenia gravis and Lambert‑Eaton syndrome

Testing contextShould be performed with associated nerve conduction studies and needle EMG to exclude neuropathy or myopathy

Required samplingAt least one motor and one sensory NCS in the clinically involved limb and distal and proximal muscles studied by needle EMG are recommended

mfVEP definition

DefinitionMultifocal visual evoked potential (mfVEP) testing assesses many visual field locations independently and concurrently to produce a topographical representation of defects

Use caseA variation of VEP used to evaluate the visual system and has been investigated for glaucoma assessment

MethodologymfVEP acquires responses from multiple visual field loci during the same test to map functional defects

Real time onsite definition

DefinitionReal time onsite refers to integrating clinical history, tailored electrodiagnostic testing, and waveform analysis while the patient is present in the laboratory under attending physician performance/supervision

Supervision standardAANEM recommends testing be performed by a physician or trained technician under direct physician supervision with one physician supervising and performing components of the exam

PurposeEnables immediate adjustment of testing and interpretation based on clinical findings

FAR (false alarm rate) definition

DefinitionFalse alarm rate (FAR) is the number of false alarms reported per 24 hours in wearable seizure detection studies

Example metricMeta-analysis reported overall FAR ~2.1 per 24 h, higher for wrist-worn (2.5/24 h) than surface devices (0.96/24 h)

Clinical relevanceHigh FAR may limit clinical utility and increase caregiver burden despite high sensitivity for tonic‑clonic seizures

GTCS / FBTCS definition

DefinitionGTCS = generalized tonic‑clonic seizure; FBTCS = focal to bilateral tonic‑clonic seizure; these are seizure types for which ILAE‑IFCN recommends clinically validated wearable detection when significant safety concerns exist

Recommendation contextILAE‑IFCN conditional recommendation for using validated wearables when alarms can enable rapid intervention (within ~5 minutes)

LimitationCurrent guidance does not recommend wearable detection for seizure types other than GTCS/FBTCS

Quantitative Sensory Testing (QST) definition

DefinitionQuantitative Sensory Testing (QST) is psychophysical testing of light touch‑pressure, vibration, thermal, and pain thresholds assessing the sensory axis from receptors to brain

Methodologic dependenceQST results are highly dependent on methodology, instrument, calibration, and full cooperation of the subject

Interpretation limitsQST abnormalities do not localize dysfunction to a specific site and should not be used as the sole diagnostic method

Surface Electromyography (sEMG) definition

DefinitionSurface electromyography (sEMG) is noninvasive recording of muscle electrical activity via skin electrodes used for monitoring respiratory muscles, neuromuscular disease assessment, and detection of generalized tonic‑clonic seizures

Clinical findingsDiagnostic accuracy is variable and depends on electrode placement and algorithm; example trial showed 76% overall sensitivity and 100% sensitivity when placed mid‑biceps

Evidence statusOverall evidence is weak and heterogeneous; further well‑designed studies needed before broad clinical adoption for many uses

Surface Mechanomyography (sMMG) definition

DefinitionSurface mechanomyography (sMMG) measures mechanical muscle output during contraction using wearable sensors and is considered the mechanical counterpart to sEMG

Typical implementationOften combined with inertial measurement units (IMUs) to assess multi‑joint range of motion, posture, gait, and muscle function

Evidence statusFew published studies exist and current evidence is insufficient to conclude a beneficial effect on health outcomes

Isolated-check Visual Evoked Potential (icVEP) definition

DefinitionIsolated‑check Visual Evoked Potential (icVEP) records visual evoked potentials using isolated‑check stimuli and reports signal‑to‑noise ratio (SNR) as a diagnostic metric

PerformanceStudies and a 2025 meta‑analysis report pooled sensitivity ~77% and specificity ~93% for glaucoma detection, but heterogeneity and protocol variability limit generalizability

SNR behaviorSNR is contrast dependent and diagnostic metrics vary with chosen SNR cutoff (e.g., cutoffs 0.85 vs 1 produced different sensitivity/specificity in Xu et al.)

Device classifications and product codes (definition)

Device regulatory classMany EMG, QST, point‑of‑care NCS, physiologic recording, and VEP devices are regulated by the FDA as Class II devices

Representative product codesFDA product codes referenced include IKN (EMG), LLN/GXB/LQW/GWI (QST), JXE (point‑of‑care NCS), and POS/GYD/GWE/HLX/GWQ (physiologic recording/VEP)

Informational useFDA classification and product codes are provided for informational/reference purposes only

Needle EMG (definition repeated for pediatric section)

Definition (pediatric)Needle electromyography requires insertion of needles through the skin into muscle to evaluate nerve, neuromuscular junction, or muscle pathology

Role in pediatric claimsFor members under 18, needle EMG performed with NCS is specified as proven and medically necessary for certain pediatric indications per policy addition

Procedural noteNeedle EMG should be performed by a trained physician as part of a comprehensive electrodiagnostic exam

SEMG / wearable monitoring definition

DefinitionSEMG/wearable monitoring refers to surface electromyography and other wearable or automated monitoring systems that record muscle electrical activity or motion signals

Use casesIncludes wearable seizure detection (surface EMG, accelerometry) and other automated monitoring systems evaluated in studies of tonic‑clonic seizure detection

Evidence cautionOverall evidence is heterogeneous; wearables show high sensitivity for tonic‑clonic seizures but have notable false alarm rates and limited validation for other seizure types